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to estimate associated direct health costs comparing the use of paracalcitol and 
cinacalcet plus low dose vitamin D over a 5-years horizon and using the Italian 
National Health System perspective. The model was developed using parameters 
from literature and assumption discussed with clinicians. National tariffs and costs 
from literature were used to value drug use, dialytic treatment, hospitalizations and 
transplant. One-way sensitivity analyses for model inputs were conducted. Costs 
and effects were discounted at 3% annum. Results: Considering 13.311 candidate 
subjects for each treatment strategy, results from the model showed a decrease in 
direct health care costs from 1.782.921.351 Euro to 1.622.357.209 Euro in favour of 
paricalcitol over 5 years. Particularly, paricalcitol produced an overall saving in drug 
costs for more than 51 millions Euro while the other direct health costs related to 
dialysis, hospitalization and transplant were reduced by approximately 109 mil-
lions Euro. ConClusions: In light of the high economic burden of end stage renal 
disease mainly associated with dialysis and transplant the use of paricalcitol for 
the treatment of IPTS in these patients represents a valid alternative not only from 
a clinical point of view but also from an economic point of view.
PUK6
AnAlysis Of BUdget imPAct Of AnemiA cOrrectiOn in rUssiAn PAtients 
With chrOnic Kidney diseAse
Ryazhenov V.V., Gorokhova S.G.
I. M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To analyze budget impact of strategies of anemia correction with 
different stimulators of erythropoiesis in patients with chronic kidney disease 
(СКD). Methods: Pharmacoeconomic analysis included cost modelling for a new 
strategy for patients with CKD and anemia that includes the use of continuous 
erythropoietin receptor activator (CERA) compared with traditional darbepoetin alfa 
(as described in ARCTOS study). The model included two stages: 1. Estimation of 
costs in 18 week correction period (phase 1 study), and 2. estimation of costs and 
effectiveness within 10 week period (phase 2 study). The costs were evaluated in 
two groups of 100 people, the first with CERA and the second with darbepoetin alfa. 
According to ARCTOS study, fewer patients treated with continuous erythropoietin 
receptor activator (CERA) required transfusion procedures compared with darbepoetin 
alfa (2.5% and 6.8%, respectively). The drugs in the study were to be administered 
under medical supervision in a day hospital. The time horizon of the study was 28 
weeks. Results: The costs of a phase 1 was 53 187.21 in CERA group and 104 528.88 
RUB in darbepoetin alfa group. The costs were almost identical in the second phase. 
The costs in darbepoetin alfa group were 2.7 times higher compared with CERA in 
respect of blood transfusion and 2 times higher in respect of drug administration. 
The cost of pharmacotherapy in CERA group was significantly lower than in group 
of darbepoetin alfa. Total costs in CERA group were 1, 7 times lower than those for 
darbepoetin alfa. ConClusions: The study demonstrates that administration of 
CERA is the most economically effective strategy for the treatment of patients with 
chronic kidney disease in Russia. It is associated with considerably lower costs com-
pared to darbepoetin alfa.
PUK7
BUdget imPAct evAlUAtiOn Of treAtment With A lOW PrOtein diet 
And KetOAnAlOgUes Of essentiAl AminOAcids fOr PrediAlysis 
PAtients in rUssiAn federAtiOn
Serpik V.G., Kulikov A.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To evaluate budget impact of low protein diet (LPD) and ketoana-
logues supply of predialysis patients in Russian Federation from Pharmacoeconomic 
perspective. Methods: Analytic decision-making model and budget impact 
analyses (BIA) were performed. Direct costs (ketoanalogues, hemodialysis, peri-
toneal dialysis, etc.) were considered. Two patients groups were compared in the 
model: ketoanalogues and LPD was administrated for the first arm in predialysis 
stage, while second arm started in the model of dialysis patients. Results of ret-
rospective efficacy analysis state, that administration of keto-analogues and LPD 
delays start of dialysis at least for one year. The following prices were used: rates of 
State medical insurance fund, Sechenov First Moscow State Medical University hos-
pitals price lists, NHS medication prices. Exchange rate: 1EURO = 40 RUB. Results: 
The first year annual costs were 23186 EURO per patient for the patients group on 
dialysis and 8620 EURO for the group of ketoanalogues. The results of BIA have 
shown that administration of ketoanalogues and LPD provides cost-saving of 14562 
EURO per patient in the first year compared with dialysis group. Total cost-saving per 
patient in the group of ketoanalogues and LPD over 5-year period was 12895 EURO 
compared with the dialysis group. ConClusions: Budget impact assessment has 
shown, that ketoanalogues and LPD in Russian Federation is a preferable technology 
and provides cost-saving of 12895 EURO over five years per patient.
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An ecOnOmic mOdel tO investigAte the BUdget imPAct in sPAin Of 
OnABOtUlinUmtOxinA tO mAnAge UrinAry incOntinence in PAtients 
With idiOPAthic OverActive BlAdder
Ruff L.1, Zeidman R.1, Aracil J.2, Loveman C.3
1Medaxial Group, London, UK, 2Allergan S.A.U., Madrid, Spain, 3Allergan Holdings Ltd.,  
Marlow, UK
objeCtives: Treatment options for patients for whom urinary incontinence (UI) 
due to idiopathic overactive bladder (OAB) is inadequately managed by anticho-
linergic therapy are limited, and can be expensive, invasive and inefficacious. This 
can lead to a significant economic burden to hospitals and health care systems. 
OnabotulinumtoxinA may provide an effective and minimally-invasive treatment 
option for OAB. An economic model was developed to investigate potential cost 
savings associated with the use of OnabotulinumtoxinA – as an adjunct to best-
supportive care (BSC) – to manage OAB rather than other treatment options in 
Spain. Methods: A prevalence-based, deterministic budget impact model with a 
five-year time horizon was developed from the perspective of the Spanish health care 
objeCtives: Automated peritoneal dialysis (APD) has been increasingly used since 
payment scheme was expanded to cover APD machine in addition to the continuous 
ambulatory peritoneal dialysis (CAPD) in the benefit package of National Health 
Insurance Program in May of 2008. This study aims to compare the health outcome 
between patients who used APD and CAPD. Methods: The including criteria were 
patients treated by APD or CAPD identified in National Health Insurance Research 
Database (NHIRD) during 2001-2010. The excluding criteria were patients who were 
treated by hemodialysis for more than 3 months before PD, or younger than 18 
years old, or received kidney transplant before. The CAPD patients and APD patients 
were identified and matched according to their propensity score predicted by age, 
gender, comorbid conditions, Charlson Comorbid Index, medication history, and 
premiums wages in the year of treatment initiation. There were 2,287 APD and 
2,287 CAPD patients entered the final analysis. The Kaplan-Meier curve and the 
Cox proportional hazard regression were performed to examine the differences 
in mortality rate, technique failure rate and incident rate of peritonitis between 
APD and CAPD. Results: There are significant differences in mortality rate (0.76% 
vs. 0.65% per patient month, p= 0.02), in technique failure rate (1.07% vs. 0.87% per 
patient month, p< 0.001), and in incidence rate of peritonitis (1.94% vs. 2.14% per 
patient month, p< 0.01) between APD and CAPD cases. When compared with CAPD, 
patients treated by APD posed higher risk in death and technique failure but no 
difference in the incidence of the 1stperitonitis with hazard ratios of 1.18 (CIs: 1.03-
1.34), 1.22 (CIs: 1.09-1.37) and 0.98 (CIs: 0.88-1.10), respectively. ConClusions: The 
APD patients seemed to have higher mortality rate and technique failure rate than 
CAPD patients, however, APD patients had lower incident rate of peritonitis than 
CAPD patients in Taiwan.
PUK3
A stUdy tO Assess diseAse PrOgressiOn tO esrd Within A yeAr in 
PAtients With AdvAnced cKd
Kumar P., Nair M., Prabhu R., Bairy M.
Manipal University, Manipal, India
objeCtives: Aimed at determining the time period for the progression to ESRD and 
also to find out the major risk factors for early progression to ESRD. Methods: A 
retrospective cohort study was conducted in a tertiary care teaching hospital. The 
data was collected from medical record dept. for the last two years (2012 and 2013) 
in hospital. Demographic details and clinical parameters of ESRD patients with 
major risk factors for early progression to ESRD were collected using the descriptive 
statistics feature of SPSS v20.0. Results: A total of 240 patients were included in 
the study. The mean age of the population was found to be 54.6±14.2 years. Majority 
of the population were males (74.83%). Hypertension 67.1%, Diabetes 47.1% and 
anemia 40.83% were the most prominent risk factors present in the study popula-
tion. More than half of the population (72.5%) took more than a year to progress to 
ESRD. ConClusions: The study revealed that males are at a higher risk of ESRD 
with half of the study cohort consisted of elderly patients (above 50 years of age). 
The study results concluded that hypertension is the most common risk factor for 
ESRD followed by diabetes and anemia. Most of the CKD patients took more than 
one year to progress to ESRD (72.5%). This information help physicians and patients 
inform decisions regarding preparation for renal replacement therapy in patients 
with advanced CKD.
PUK4
Be cAUtiOUs Of triPle WhAmmy!!!
Zulkifly H., Abdul Wahab M.S., Shaharuddin S., Chiau Ming L., Mat Zaid H.
Universiti Teknologi MARA, Selangor, Malaysia
objeCtives: This study was aimed to identify the occurrence of concomitant pre-
scribing of NSAIDs, ACE Inhibitors (ACEI) and diuretics known as triple whammy 
received by out-patients at a Malaysian teaching hospital. It also aimed to identify the 
relationship between prescriptions of triple whammy with specific age. Methods: 
A retrospective, observational study was performed in a general teaching hospital. 
The patients’ prescriptions (January-March 2012) from the outpatient pharmacy 
department that were prescribed with NSAIDs, ACE Inhibitors (ACEI) and diuretics 
were reviewed and recorded. The association between the prescriptions with age was 
investigated. Statistical analysis was done using SPSS with significance difference 
determined by p value of < 0.05. Results: Four hundred and twenty four patients 
(56.1% male) were included. Four hundred and twenty two patients were taking one or 
more of NSAIDs, ACEI and diuretic and only 2 patients were taking all three. Majority 
of our patients (40.1%) received the combination of ACEI and diuretics. Combination 
of ACEI and diuretics were mainly (21.7%) prescribed to patients above 65 years old 
(p= 0.362). ConClusions: The occurrence of triple whammy at a teaching hospital 
during the period of data collection is low. This is indeed a good predictor of safe pre-
scribing of drugs among physicians as concomitant use of these three medications 
may impair renal function especially in the elderly and dehydrated patients. Majority 
of the patients that were prescribed with combination of diuretics and ACEI are above 
65 years old, therefore proper monitoring of their renal function and the hydration 
status should be performed to reduce the risk of renal insufficiency in the future.
UrinAry/Kidney disOrders – cost studies
PUK5
A BUdget imPAct AnAlysis (BiA) Of the Use Of PAricAlcitOl fOr the 
treAtment Of secOndAry hyPerPArAthyrOidism (shPt) in end stAge 
renAl diseAse PAtients
Lorenzoni V., Pierotti F., Turchetti G.
Scuola Superiore Sant’Anna, Pisa, Italy
objeCtives: Budget impact analysis (BIA) of the use of paricalcitol versus alterna-
tive treatment for the management of secondary hyperparathyroidism (SHPT) in 
end stage renal disease patients. Methods: A Markov model was used to simulate 
the evolution of end stage renal disease patients trough transplant and death and 
